‘Incredible’ results seen with intravitreal phase 2 gene therapy for wet AMD

In this video interview, Sunir J. Garg, MD, FACS, FASRS, discussed 2-year results of the phase 2 LUNA study on ixoberogene soroparvovec, an intravitreal gene therapy from Adverum Biotechnologies for wet age-related macular degeneration.The results were presented at the American Society of Retina Specialists annual meeting.